News summary
Sunflower Pharmaceutical: Compound Polyethylene Glycol (3350) Electrolyte Powder has been accepted for listing approval. Securities Times Company e News, Sunflower Pharmaceutical (002737) announced on the evening of May 5 that its wholly-owned subsidiary Harbin Sunflower Pharmaceutical Co., Ltd.(referred to as "Ha Sunflower") recently received a receipt from the State Drug Administrationdbbingo...
Newsletter text
Sunflower Pharmaceutical: Compound Polyethylene Glycol (3350) Electrolyte Powder has been accepted for listing approval. Securities Times Company e News, Sunflower Pharmaceutical (002737) announced on the evening of May 5 that its wholly-owned subsidiary Harbin Sunflower Pharmaceutical Co., Ltd.(referred to as "Ha Sunflower") recently received a issuance from the State Drug AdministrationdbbingoThe "Acceptance Notice" on the application for registration and marketing authorization of Compound Polyethylene Glycol (3350) Electrolyte Powder proposes indications (or functional indications): for the treatment of chronic constipation in children aged 1 to 11 and fecal impaction in children aged 5 to 11.
